JAK1/2 inhibitor. Dysregulated JAK-STAT pathway in CTCL leads to T-cell activation. Phase II trial showed 23% ORR. This evidence concerns the gene JAK1 and primary cutaneous T-cell non-Hodgkin lymphoma.